Company / SG&A Expense
IDEAYA Biosciences, Inc. SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$63.3M
FY2025
5-year range
$10.0M / $63.3M
FY2021-FY2025
Trend
+61.1%
vs FY2024
Sector context
#142 of 213
Health Care
What the data says
At $63M, IDEAYA Biosciences, Inc.'s sg&a expense ranks #72 of 213 in the Health Care sector. SG&A Expense has increased for 5 consecutive years, from $5M in FY2020 to $63M in FY2025.
Based on SEC 10-K filings.
$63M in FY2025 with a 5-year CAGR of +68.5%.
Increased from $28M to $63M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +61.0%
- 5-Year CAGR
- +68.5%
- 10-Year CAGR
- -
Sector benchmark
#72 of 213 in Health CareTop 33% of 213This company $63.3M Sector average $722.3M
▼
-91.2% below sector average
Key checks
Key Insights
- IDEAYA Biosciences, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +68.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 61.1% year-over-year.
- Ranks #142 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 4.55 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $63.3M | +61.1% |
| FY2024 | $39.3M | +38.8% |
| FY2023 | $28.3M | +86.4% |
| FY2022 | $15.2M | +52.6% |
| FY2021 | $10.0M | +113.2% |
| FY2020 | $4.7M | -53.1% |
| FY2019 | $10.0M | +113.2% |
| FY2018 | $4.7M | +127.3% |
| FY2017 | $2.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026